延长长春新碱和地塞米松脉冲治疗对TCF3-PBX1阳性急性淋巴细胞白血病儿童可能并非必要
在CCCG-ALL-2015试验中,263例新诊断TCF3-PBX1阳性急性淋巴细胞白血病儿童按1:1随机接受额外7次长春新碱和地塞米松脉冲治疗(对照组)或不接受(试验组)。中位随访4.2年,5年无事件生存率和总生存率两组无显著差异,非劣效性成立,提示治疗超过一年后省略脉冲治疗不影响结局。
要点
- 中位随访4.2年,对照组5年无事件生存率90.1% vs 试验组89.2%,5年总生存率94.7% vs 95.6%。
- 非劣效性成立:5年无事件生存率差异单侧95%置信上限为0.003,总生存率为0.01。
- 治疗超过一年后省略长春新碱和地塞米松脉冲治疗不影响TCF3-PBX1阳性急性淋巴细胞白血病儿童结局。
核心结论
- 治疗超过一年后省略长春新碱和地塞米松脉冲治疗不影响TCF3-PBX1阳性急性淋巴细胞白血病儿童的结局。
研究设计与样本
- CCCG-ALL-2015临床试验(ChiCTR-IPR-14005706)的非劣效性分析,2015年1月至2019年12月纳入263例新诊断TCF3-PBX1阳性急性淋巴细胞白血病儿童,按1:1随机分层分配接受额外7次长春新碱和地塞米松脉冲治疗(对照组)或不接受(试验组)。
主要发现
- 两组基线特征无显著差异。
- 中位随访4.2年,对照组5年无事件生存率为90.1%(95% CI 85.1-95.4),试验组为89.2%(95% CI 84.1-94.7)。
- 对照组5年总生存率为94.7%(95% CI 90.9-98.6),试验组为95.6%(95% CI 91.8-99.6)。
- 按治疗分析,5年无事件生存率差异的单侧95%置信上限为0.003,5年总生存率差异的单侧95%置信上限为0.01,非劣效性成立。
关键数值与推荐
- 5年无事件生存率:对照组90.1%(95% CI 85.1-95.4) vs 试验组89.2%(95% CI 84.1-94.7)。
- 5年总生存率:对照组94.7%(95% CI 90.9-98.6) vs 试验组95.6%(95% CI 91.8-99.6)。
- 非劣效性界值:5年无事件生存率差异单侧95%置信上限0.003,5年总生存率差异单侧95%置信上限0.01。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The effect of prolonged pulse therapy with vincristine and dexamethasone (VD) during maintenance therapy on the outcome of paediatric patients with TCF3-PBX1 positive acute lymphoblastic leukaemia (ALL) remains uncertain. We conducted non-inferiority analysis of 263 newly diagnosed TCF3-PBX1 positive ALL children who were stratified and randomly assigned (1:1) to receive seven additional VD pulses (the control group) or not (the experimental group) in the CCCG-ALL-2015 clinical trial from January 2015 to December 2019 (ChiCTR-IPR-14005706). There was no significant difference in baseline characteristics between the two groups. With a median follow-up of 4.2 years, the 5-year event-free survival (EFS) and 5-year overall survival (OS) in the control group were 90.1% (95% confidence interval [CI] 85.1-95.4) and 94.7% (95% CI, 90.9-98.6) comparable to those in the experimental group 89.2% (95% CI 84.1-94.7) and 95.6% (95% CI 91.8-99.6), respectively. Non-inferiority was established as a one-sided 95% upper confidence bound for the difference in probability of 5-year EFS was 0.003, and that for 5-year OS was 0.01 by as-treated analysis. Thus, omission of pulse therapy with VD beyond one year of treatment did not affect the outcome of children with TCF3-PBX1 positive ALL.
引用
- Wan Y, Zhang H, Zhang L, et al. Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia. Br J Haematol. 2022. PMID: 36114009. doi:10.1111/bjh.18437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。